Zobrazeno 1 - 10
of 338
pro vyhledávání: '"PTC299"'
Autor:
Baiazitov, Ramil Y., Qi, Hongyan, Arasu, Tamil, Lennox, William, Cao, Liangxian, Weetall, Marla, Furia, Bansri, Zhuo, Jin, Choi, Soongyu, Kim, Min Jung, Sheedy, Josephine, Davis, Thomas, Moon, Young-Choon
Publikováno v:
In European Journal of Medicinal Chemistry 15 December 2022 244
Autor:
Weetall, Marla1, Davis, Thomas1, Elfring, Gary1, Northcutt, Valerie1, Cao, Liangxian1, Moon, Young‐Choon1, Riebling, Peter1, Dali, Mandar1, Hirawat, Samit2, Babiak, John1, Colacino, Joseph1, Almstead, Neil1, Spiegel, Robert1, Peltz, Stuart W.1
Publikováno v:
Clinical Pharmacology in Drug Development. Jul/Aug2016, Vol. 5 Issue 4, p296-305. 10p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stuart W. Peltz, Joseph M. Colacino, Art Branstrom, Neil G. Almstead, Allan Jacobson, Thomas W. Davis, John Babiak, Young-Choon Moon, Janet Petruska, Ronald Kong, William Lennox, Seongwoo Hwang, Tamil Arasu, Hongyan Qi, Shirley Yeh, Nicole Risher, Jean Hedrick, Josephine Sheedy, Joshua Du, Wencheng Li, Jason D. Graci, Charles Romfo, Bansri Furia, Min Jung Kim, Jiyuan Ma, Katherine Cintron, Christopher Trotta, Marla Weetall, Liangxian Cao
PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b38cf3c29f914ea98d3f3c7be961d2f
https://doi.org/10.1158/1535-7163.c.6539454.v1
https://doi.org/10.1158/1535-7163.c.6539454.v1
Autor:
Stuart W. Peltz, Joseph M. Colacino, Art Branstrom, Neil G. Almstead, Allan Jacobson, Thomas W. Davis, John Babiak, Young-Choon Moon, Janet Petruska, Ronald Kong, William Lennox, Seongwoo Hwang, Tamil Arasu, Hongyan Qi, Shirley Yeh, Nicole Risher, Jean Hedrick, Josephine Sheedy, Joshua Du, Wencheng Li, Jason D. Graci, Charles Romfo, Bansri Furia, Min Jung Kim, Jiyuan Ma, Katherine Cintron, Christopher Trotta, Marla Weetall, Liangxian Cao
Supplementary Figures S1-S7: Supplementary Figure S1 shows chemical Synthesis and biological characterization of PTC299. Supplementary Figure S2 shows generation and characterization of PTC299-resistant HT1080 cells. Supplementary Figure 3 shows that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24ac4776ab8dbd1c4bd81dcd8bb2dab7
https://doi.org/10.1158/1535-7163.22509942
https://doi.org/10.1158/1535-7163.22509942
Autor:
Stuart W. Peltz, Joseph M. Colacino, Art Branstrom, Neil G. Almstead, Allan Jacobson, Thomas W. Davis, John Babiak, Young-Choon Moon, Janet Petruska, Ronald Kong, William Lennox, Seongwoo Hwang, Tamil Arasu, Hongyan Qi, Shirley Yeh, Nicole Risher, Jean Hedrick, Josephine Sheedy, Joshua Du, Wencheng Li, Jason D. Graci, Charles Romfo, Bansri Furia, Min Jung Kim, Jiyuan Ma, Katherine Cintron, Christopher Trotta, Marla Weetall, Liangxian Cao
contains the raw data from the Microarrays study in the PTC299-resistant HT1080 cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ffd21a73c725157d53ebd64ecdca72
https://doi.org/10.1158/1535-7163.22509948.v1
https://doi.org/10.1158/1535-7163.22509948.v1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ramil Y. Baiazitov, Hongyan Qi, Tamil Arasu, William Lennox, Liangxian Cao, Marla Weetall, Bansri Furia, Jin Zhuo, Soongyu Choi, Min Jung Kim, Josephine Sheedy, Thomas Davis, Young-Choon Moon
Publikováno v:
European journal of medicinal chemistry. 244
Dihydroorotate dehydrogenase (DHODH) is the enzyme that catalyzes a rate-determining step during the de novo synthesis of uridine, an important source of cellular pyrimidine nucleotides. Ability to modulate the activity of this enzyme may be used to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::167f187008bc398fdc713f7fe29ef098
https://pubmed.ncbi.nlm.nih.gov/36242990
https://pubmed.ncbi.nlm.nih.gov/36242990
Autor:
Caterina Strambio-De-Castillia, Stuart W. Peltz, Christopher R. Trotta, Joseph M. Colacino, Elizabeth Goodwin, Liangxian Cao, Yetao Wang, Ellen L Suder, Elke Mühlberger, Sina Bavari, Jason D. Graci, Allan Jacobson, Mark Pykett, Kylie O'Keefe, Rachel A. Sattler, Ronald Kong, Ellen Welch, Jeremy Luban, Katherine Cintron-Lue, Marla Weetall, Slobodan Paessler, Veronica Soloveva, Nikolai Naryshkin
Publikováno v:
Virus Research
bioRxiv
bioRxiv
Highlights • COVID-19 is typified by SARS-CoV-2 replication and excessive inflammatory response. • PTC299 is small orally available DHODH inhibitor that blocks pyrimidine synthesis. • PTC299 is potent inhibitor of the replication of SARS-CoV-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3cffc893d893918d7de424f44edd7c5
https://doi.org/10.1016/j.virusres.2020.198246
https://doi.org/10.1016/j.virusres.2020.198246